Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.62 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.57 |
| ▸ | MTOR | P42345 | 13/20 | 0.57 |
| ▸ | ABL1 | P00519 | 13/20 | 0.57 |
| ▸ | SRC | P12931 | 13/20 | 0.57 |
| ▸ | PRKDC | P78527 | 13/20 | 0.57 |
| ▸ | EGFR | P00533 | 12/20 | 0.57 |
| ▸ | HCK | P08631 | 12/20 | 0.57 |
| ▸ | KDR | P35968 | 12/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18799891 | 0.93 | PIK3CD (0.57) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL8012344 | 0.92 | PIK3CD (0.56) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL8006833 | 0.91 | KDR (0.56) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL8006218 | 0.90 | SRC (0.55) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL12651288 | 0.90 | ABL1 (0.55) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL12422410 | 0.88 | PIK3CG (0.61) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1785138 | 0.88 | SRC (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBMTOR | |
| SCHEMBL12607037 | 0.85 | PIK3CG (0.72) | PIK3CDPIK3C2BPIK3CGPIK3CAPIK3CB | |
| SCHEMBL8008773 | 0.85 | SRC (0.59) | PIK3CDPIK3CGPIK3CAPIK3CBMTOR | |
| SCHEMBL8012348 | 0.85 | SRC (0.56) | PIK3CDPIK3CGPIK3CAPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | INTELLIKINE LLC | 2015-08-13 | — | — | US | disclosed |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | INTELLIKINE LLC | 2015-08-13 | — | — | US | disclosed |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | INTELLIKINE LLC | 2015-08-13 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | PIK3CD 22/4885PIK3C2B 24/4885PIK3CG 33/4885 |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | MTOR, PDPK1, PIKFYVE | PIK3CD 22/4885PIK3C2B 24/4885PIK3CG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.